Navigation Links
Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017
Date:8/31/2010

NEW YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue:

Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0254468/Hormone-Replacement-Therapy-in-Menopause---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData's has released its pharmaceutical and healthcare report, "Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global menopause hormone therapy market. The report identifies the key trends shaping and driving the global menopause hormone therapy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global menopause hormone therapy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. GlobalData estimated the global hormone therapy (HT) market to be worth $2.4 billion in 2009, indicating a Compound Annual Growth Rate (CAGR) of -5.9% between 2001 and 2009. This decline in the market is mainly attributed to poor patient compliance as a result of the serious safety concerns associated with hormones. By 2017, the market is forecast to be worth $2.8 billion, with a CAGR of 2.2% between 2009 and 2017. The market is restrained by factors such as the poor acceptance of hormone therapies in patients and physicians. Increased interest in low-dose and ultra-low dose hormone therapies are expected to lead to marginal growth of the HT market.

Scope

The report provides information on the key drivers and challenges in the menopause hormone therapy market. Its Scope includes:

- Annualized global menopause hormone therapy market revenues data from 2001 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. These drugs are estrogens or progestins (including combination therapies and low-dose therapies), non-hormonal products such as serum estrogen receptor modulators, serotonin reuptake inhibitors, estrogen receptor alpha agonists, among others.

- Analysis of the current and future competition in the global menopause hormone therapy market. The key market players covered are Pfizer, Merck & Co, Amgen, BioSante Pharmaceuticals, Noven Pharmaceuticals, Bionovo, QuatRx Pharmaceuticals and Depomed.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hormone replacement therapy market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global menopause hormone therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global menopause hormone therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global menopause hormone therapy market landscape? – Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Hormone Replacement Therapeutics: Introduction 6

2.1 GlobalData Pipeline Report Guidance 7

2.2 Concerns Raised Regarding the Safety of Hormone Therapy 8

2.2.1 WHI study 8

2.2.2 Million Women Study 8

2.2.3 Heart and Estrogen/Progestin Replacement Study (HERS) 9

2.2.4 Women's Angiographic Vitamin and Estrogen (WAVE trial) 9

2.2.5 Women's Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELLHART trial) 9

2.2.6 Estrogen Replacement and Atherosclerosis (ERA) study 10

2.2.7 WHI Memory Study (WHIMS study) 10

2.2.8 Postmenopausal Estrogen/Progestin Interventions (PEPI) study 10

2.2.9 Scientific Evidence and Perceptions about the Safety and Efficacy of Hormone Therapy 10

2.2.10 Conclusion 12

2.3 Hormone Replacement Therapy Market Size 13

2.4 Hormone Replacement Therapy Market Forecast and CAGR 13

2.5 Drivers and Barriers for the Hormone Replacement Therapy Market 15

2.5.1 Drivers for the Hormone Replacement Therapy Market 15

2.5.2 Restraints for the Hormone Replacement Therapy Market 15

2.6 Opportunity and Unmet Need 16

2.7 Key Takeaway 17

3 Hormone Replacement Therapy Market: Competitive Assessment 18

3.1 Overview 18

3.2 Strategic Competitor Assessment 18

3.3 Product Profile for the Major Marketed and Off-label Products in the Hormone Therapy Market 19

3.3.1 Enjuvia (synthetic conjugated estrogens, B) 19

3.3.2 Femtrace (estradiol acetate) 21

3.3.3 Premarin (conjugated estrogens) 22

3.3.4 Estrace (estradiol) 24

3.3.5 Femring (estradiol acetate vaginal ring) 25

3.3.6 Vagifem (estradiol vaginal tablets) 27

3.3.7 Transdermal and Topical Estrogen Therapy Products for Postmenopausal Use 28

3.3.8 Menostar (estradiol transdermal) 28

3.3.9 Mirena (levonorgestrel-releasing intrauterine system) 30

3.3.10 Prochieve (Progesterone gel) 30

3.3.11 Prempro (Conjugated Estrogens/ Medroxyprogesterone Acetate Tablets) 31

3.4 Key Takeaway 33

4 Hormone Therapy Market: Pipeline Assessment 34

4.1 Overview 34

4.2 Strategic Pipeline Assessment 34

4.2.1 Technology Trends Analytic Framework 34

4.3 Hormone Therapy – Promising Drugs under Clinical Development 36

4.4 Molecule Profile for Promising Drugs under Clinical Development 37

4.4.1 Aprela (Bazedoxifene/Conjugated Estrogen) 37

4.4.2 Serada (Gabapentin, DM-5689) 38

4.4.3 Odanacatib (MK-0822) 38

4.4.4 Ophena (Ospemifene) 39

4.4.5 ALX1-11 (PREOS, parathyroid hormone 1-84 [rDNA origin] injection) 40

4.4.6 Menerba (MF-101) 41

4.4.7 Pristiq (Desvenlaxafine, DVS-233) 42

4.4.8 Mesafem (low-dose paroxetine mesylate) 43

4.4.9 LibiGel (Testosterone gel) 43

4.5 Hormone Therapy Market – Clinical Pipeline by Mechanism of Action 44

4.6 Hormone Therapy Pipeline – Pipeline by Phase of Clinical Development 45

4.6.1 Hormone Therapy – Phase III Pipeline 46

4.6.2 Hormone Therapy – Phase II Pipeline 47

4.6.3 Hormone Therapy – Phase I Pipeline 48

4.6.4 Hormone Therapy – Preclinical Pipeline 49

4.6.5 Hormone Therapy – Discovery Pipeline 50

4.7 Discontinued / Suspended Drugs for Hormone Replacement Therapy 50

4.8 Key Takeaway 51

5 Hormone Replacement Therapeutics Market: Implications for Future Market Competition 52

6 Hormone Therapy Market: Future Players in Hormone Therapy Market 54

6.1 Introduction 54

6.2 Pfizer 54

6.2.1 Company Overview 54

6.2.2 Business Description 55

6.2.3 Hormone Therapeutics Portfolio 56

6.3 Merck & Co. 57

6.3.1 Company Overview 57

6.3.2 Business Description 57

6.3.3 Hormone Therapeutics Portfolio 58

6.4 Amgen 58

6.4.1 Company Overview 58

6.4.2 Business Description 59

6.4.3 Hormone Therapeutics Portfolio 60

6.5 BioSante Pharmaceuticals 60

6.5.1 Company Overview 60

6.5.2 Business Description 60

6.5.3 Hormone Therapeutics Portfolio 61

6.6 Noven Pharmaceuticals 61

6.6.1 Company Overview 61

6.6.2 Business Description 61

6.6.3 Hormone Therapeutics Portfolio 62

6.7 Bionovo, Inc. 62

6.7.1 Company Overview 62

6.7.2 Business Description 62

6.7.3 Hormone Therapeutics Portfolio 63

6.8 QuatRx Pharmaceuticals Company 63

6.8.1 Company Overview 63

6.8.2 Hormone Therapeutics Portfolio 64

6.9 Depomed Inc. 64

6.9.1 Company Overview 64

6.9.2 Business Description 64

6.9.3 Hormone Therapeutics Portfolio 65

7 Hormone Therapeutics Market: Appendix 66

7.1 Definitions 66

7.2 Acronyms 66

7.3 Scope of Pipeline Research 68

7.4 Research Methodology 68

7.4.1 Coverage 69

7.4.2 Secondary Research 69

7.4.3 Forecasting 69

7.4.4 Primary Research 72

7.4.5 Expert Panel validation 72

7.5 Contact Us 72

7.6 Disclaimer 72

7.7 Sources 73

1.1 List of Tables

Table 1: Hormone Therapeutics, Global, Market Revenue ($bn), 2001-2009 13

Table 2: Hormone Therapeutics, Global, Market Forecast ($bn), 2009-2017 14

Table 3: Hormone Replacement Therapy, Most Promising Drugs Under Clinical Development, 2010 36

Table 4: Hormone Therapeutics, Global, Osteoporosis, Phase III Pipeline, 2010 46

Table 5: Hormone Therapeutics, Menopause, Global, Phase III Pipeline, 2010 46

Table 6: Hormone Therapeutics, Osteoporosis, Global, Phase II Clinical Pipeline, 2010 47

Table 7: Hormone Therapeutics, Menopause, Global, Phase II Clinical Pipeline, 2010 47

Table 8: Hormone Therapeutics, Osteoporosis, Global, Phase I Clinical Pipeline, 2010 48

Table 9: Hormone Therapeutics, Menopause, Global, Phase I Clinical Pipeline, 2010 48

Table 10: Hormone Therapeutics, Osteoporosis, Global, Preclinical Pipeline, 2010 49

Table 11: Hormone Therapeutics, Menopause, Global, Preclinical Pipeline, 2010 49

Table 12: Hormone Therapeutics, Osteoporosis, Global, Discovery Pipeline, 2010 50

Table 13: Hormone Therapy, Global, Discontinued Drugs, 2010 50

Table 14: Hormone Therapeutics, Global, Pfizer Pipeline Drugs, 2010 56

Table 15: Hormone Therapeutics, Global, Merck & Co. Pipeline Drugs, 2010 58

Table 16: Hormone Therapeutics, Global, Amgen Pipeline, 2010 60

Table 17: Hormone Therapeutics, Global, BioSante Pipeline, 2010 61

Table 18: Hormone Therapeutics, Global, Noven Pipeline, 2010 62

Table 19: Hormone Therapeutics, Global, Bionovo Pipeline, 2010 63

Table 20: Hormone Therapeutics, Global, QuatRx Pipeline, 2010 64

Table 21: Hormone Therapeutics, Global, Depomed Pipeline, 2010 65

1.2 List of Figures

Figure 1: Hormone Therapeutics, Global, Market Revenue ($bn), 2001-2009 13

Figure 2: Hormone Therapeutics, Global, Market Forecast ($bn), 2009-2017 14

Figure 3: Opportunity and Unmet Need, Hormone Replacement Therapy, 2010 16

Figure 4: Strategic Competitor Assessment of Major Marketed Products, Hormone Therapy, 2010 19

Figure 5: Hormone Therapy, Menopause, Technology Trends Analytic Framework , 2010 34

Figure 6: Hormone Therapy, Menopause, Technology Trends Analytic Framework - Description , 2010 35

Figure 7: Hormone Therapy Market – Clinical Pipeline by Mechanism of Action, 2010 45

Figure 8: Hormone Therapy, Global, Pipeline by Phases of Clinical Development, 2010 45

Figure 9: Implications for Future Market Competition in the Hormone Therapy Market, 2010 52

Figure 10: Hormone Therapy Market, Global, Clinical Pipeline by Company, 2010 54

Figure 11: GlobalData Methodology, 2010 68

Figure 12: GlobalData Market Forecasting Model, 2010 71

Companies mentioned

Pfizer

Merck & Co.

Amgen

BioSante Pharmaceuticals

Noven Pharmaceuticals

Bionovo, Inc.

QuatRx Pharmaceuticals Company

Depomed Inc.

To order this report:

Pharmaceutical Industry: Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
2. Reportlinker Adds Threats to Avastin - Targeting the VEGF Pathway
3. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
4. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
5. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
6. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
7. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
8. Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets
9. Reportlinker Adds Production and Market of Xylose in China
10. Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED
11. Reportlinker Adds European Markets for Small Joint Reconstructive Devices 2010 (15 Countries)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):